Financials
Financial year 2025
WE-PHARMA from Huy, company number BE0810070556, closed financial year 2025 with a result of € -2.2 million after tax. For that financial year WE-PHARMA recorded a gross margin of € 1.2 million and equity of € 1.4 million. Compared with financial year 2024, the result moved from € 4,235 to € -2.2 million. The company made a loss. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.
€ 1.4 million
▲ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.2 million
▼ still € 4,235 profit in 2024
Profit after tax over the fiscal year.
€ 24,738
▲ 60% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.1 million.
People and assets in 2025
19.6
▲ 4.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.1 million
▲ 38% vs 2024
€ 54,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 496,705
▼ 24% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2.9 million
▲ 78% vs 2024
€ 130,895 is repaid this year. At this pace the long-term loan is gone in ≈ 16 years.
€ 175,133
▲ 142% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 61,722
▼ 51% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | - | € 2,344,618 | - | |
| Gross margin | € 525,179 | € 567,247 | € 1,277,623 | € 1,229,420 | ▼ 4% |
| Profit after taxes | € 21,740 | € 9,342 | € 4,235 | € -2,236,546 | ▼ € 2.2 million |
| Equity | € 132,386 | € 141,728 | € 1,275,963 | € 1,385,519 | ▲ 9% |
| Total debts | € 1,528,481 | € 1,911,132 | € 2,190,540 | € 3,128,929 | ▲ 43% |
| Cash | € 56,982 | € 85,357 | € 15,489 | € 24,738 | ▲ 60% |
| Land & buildings | € 220,870 | € 214,195 | € 456,289 | € 466,668 | ▲ 2% |
| Retained profit | € 90,186 | € 99,528 | € 103,763 | € -2,132,783 | ▼ € 2.2 million |
| Bank debt | € 1,068,751 | € 1,360,905 | € 1,624,281 | € 2,892,075 | ▲ 78% |
| Balance sheet total | € 1,660,867 | € 2,052,860 | € 3,466,502 | € 4,514,448 | ▲ 30% |
| Employees (FTE) | - | 504,402.7 | 14.9 | 19.6 | ▲ 4.7 |
Key figures of WE-PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to WE-PHARMA?
What happened at WE-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 2.2 million (▼ € 2.2 million vs 2024). filed late Source: NBB ↗
- Nathalie Brusselaers stepped down as director. NBB
- ISLA stepped down as director. NBB
- Capital increase of € 288,289, published in the Gazette. Source: Staatsblad ↗
- Capital increase of € 1.4 million, published in the Gazette. Source: Staatsblad ↗
- Capital increase of € 695,064, published in the Gazette. Source: Staatsblad ↗
- Toralius became a director. NBB
- Assurance des Collines became a director. NBB
In short
From € 21,740 profit in 2022 to € 2.2 million loss in 2025.
Paid € 44,200 in corporate taxes since 2022.
Best year ever: 2022, with € 21,740 profit.
On average € 62,700 of value added per employee in 2025.
Management
The stake of SAGAFIL, AFKIR HAFIDA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
WE-PHARMABehind WE-PHARMA are Toralius and Assurance des Collines. The shares are held by SAGAFIL (88.4%) and AFKIR HAFIDA (1.8%).
Directors
According to the 2025 annual accounts
since 2025
since 2025
Nathalie Brusselaers
Director
since 2025 · until 2026
Director · represented by Stéfan Otte
since 2025 · until 2026
Shareholders
88.4%
1.8%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Sous-le-Château 51
4500 Huy
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Capital increase
Source: Deed ↗- BRUSSELAERS Vincent(bestaande vennoot (actionnaire)) 2.4%
- DRION Charles-Antoine(bestaande vennoot (actionnaire)) 2.4%
- CH INVEST(nieuwe vennoot) 1.3%
- BUNKENS Geert(bestaande vennoot (actionnaire)) 0.8%
Capital increase
Source: Deed ↗- BRUSSELAERS Nathalie Jocelyne Francine(apporteur) 9.8%
- OTTE Stefan(apporteur) 8.7%
- ASSURANCES DES COLLINES(apporteur) 4.3%
- JOURET SANDRINE(apporteur) 3.6%
- DRION Charles-Antoine(apporteur) 2.9%
- DARMON Marc(apporteur) 1.8%
- HERTELEER Nina(apporteur) 1.8%
- SBaye Consulting(apporteur) 1%
- TORALIUS(apporteur) 0.5%
- NEUKERMANS Jan Hedwig Alfons(apporteur) 0.5%
Capital increase
Source: Deed ↗- ASSURANCES DES COLLINES(inschrijver) 3.7%
- OTTE Stefan(inschrijver) 3.7%
- TORALIUS(inschrijver) 3.7%
- MARCUZZO Lucia(inschrijver) 3.7%
- BOUZERDA Ali(inschrijver) 2.8%
- BRUSSELAERS Nathalie Jocelyne Francine(inschrijver) 2.2%
- JOURET SANDRINE(inschrijver) 1.9%
- SBaye Consulting(inschrijver) 1.1%
- HERTELEER Nina(inschrijver) 0.9%
- BRUSSELAERS Vincent(inschrijver) 0.9%
- DARMON Marc(inschrijver) 0.9%
- DONCK Thomas(inschrijver) 0.2%
Capital increase
Source: Deed ↗- AKFIR Hafida(intekenaar) 0.9%
- ZIRARI Meriem(intekenaar) 0.9%
- ASSURANCES DES COLLINES(intekenaar) 0.7%
- ADDA Rachid et Madame EL BARIAKI Radia(intekenaar) 0.7%
- TMEITI Hayet(intekenaar) 0.7%
- BRUSSELAERS Nathalie Jocelyne Francine(intekenaar) 0.6%
- DONCK Thomas Paul Luc(intekenaar) 0.6%
- DARMON Marc(intekenaar) 0.3%
- HERTELEER Nina(intekenaar) 0.3%
- SBaye Consulting(intekenaar) 0.3%
Capital increase
Source: Deed ↗- ASSURANCES DES COLLINES(inbrenger, bestaande aandeelhouder) 3.9%
- TMEITI Karima(inbrenger, nieuwe aandeelhouder) 3.1%
- ADDA Rachid en EL BARIAKI Radia(inbrenger, nieuwe aandeelhouder (echtgenoten)) 1.6%
- BRUSSELLAERS Nathalie Jocelyne Francine(inbrenger, bestaande aandeelhouder) 1.3%
- TMEITI Hayet(inbrenger, nieuwe aandeelhouder) 1.3%
- HT CONSULTING(inbrenger, nieuwe aandeelhouder) 1.1%
- AFKIR HAFIDA(inbrenger, bestaande aandeelhouder) 0.9%
- DARMON Marc(inbrenger, bestaande aandeelhouder) 0.8%
- HERTELEER Nina(inbrenger, bestaande aandeelhouder) 0.8%
- OTTE Stefan Elisa Omer(inbrenger, bestaande aandeelhouder) 0.6%
- SBaye Consulting(inbrenger, nieuwe aandeelhouder) 0.6%
- STICHELMANS Marie-Elise Philippine(inbrenger, nieuwe aandeelhouder) 0.6%
- BRUSSELAERS Vincent Emmanuel René(inbrenger, nieuwe aandeelhouder) 0.6%
- DJENNANE Frank Robert(inbrenger, nieuwe aandeelhouder) 0.5%
- TORALIUS(inbrenger, bestaande aandeelhouder) 0.3%
Incorporation
Source: Deed ↗- COMTE Nancy Yvonne Ghislaine(oprichter/vennoot) 50%
- GERARD Laurence Julienne Marie-Josèphe(oprichter/vennoot) 50%
Details
- Company number
- 0810.070.556
- VAT number
- BE 0810.070.556
- Registered office
- Rue Sous-le-Château 51, 4500 Huy
- Names & denominations
- WE-PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 February 2009
- Peppol
- Active · Active since 23 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van verpakkingsbedrijven